Erratum for Duvic et al., Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

In the article by Duvic et al entitled “Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL),” which appeared in the January 1, 2007, issue of Blood (Volume 109:31–39), Table 6 contained 4 inaccurate column subheadings. The 4 subheadings under “All patients by grade” should have been “Grade 1,” “Grade 2,” “Grade 3,” and “Grade 4.”